Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
The third and last podcast from our discussions with Dr. Lecia Sequist, of Massachusetts General Hospital and Harvard Medical School, covers the question & answer session that followed her excellent webinar on acquired resistance to EGFR tyrosine kinase inhibitors, as well as the update I did with her on the latest information from their experience of re-biopsying lung tumors over the course of treatment.
Here are the audio and video versions of the podcast, as well as the transcript.
[powerpress]
sequist-qa-session-audio-podcast
I'll note that we didn't include every question, but these are many of them that would likely be most appealing to a broad audience. Feel free to leave other questions, and either one of us on the GRACE faculty or perhaps Dr. Sequist may be able to provide some thoughts.
I hope people learned something from the webinar and the series of podcasts.
Please feel free to offer comments and raise questions in our
discussion forums.
Hi app.92, Welcome to Grace. I'm sorry this is late getting to you. And more sorry your mum is going through this. It's possible this isn't a pancoast tumor even though...
A Brief Tornado. I love the analogy Dr. Antonoff gave us to describe her presentation. I felt it earlier too and am looking forward to going back for deeper dive.
Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".
While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".
I hope any...
My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.
Here's the webinar on YouTube. It begins with the agenda. Note the link is a playlist, which will be populated with shorts from the webinar on specific topics
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.